Pathology of incipient pancreatic cancer.

BACKGROUND An understanding of incipient pancreatic neoplasia is an essential foundation for the future development of effective screening tests for pancreatic cancer. Only when we understand early pancreatic neoplasms will we be able to detect tumors that are curable with surgical resection. METHOD Two approaches have helped define incipient pancreatic neoplasia. First, the histologic examination of pancreata has helped identify the most common histologic lesions in pancreatic tissues adjacent to infiltrating carcinomas. The assumption is that some of these lesions represent the precursors to the infiltrating cancers. Second, advances in molecular genetics now make it possible to define the genetic alterations present in small lesions. The demonstration that a suspected precursor lesion and an infiltrating pancreatic carcinoma share the same genetic alterations would help establish that the lesion is indeed a precursor to infiltrating pancreatic carcinoma. RESULTS A spectrum of intraductal proliferations in the pancreas has been found associated with infiltrating adenocarcinoma of the pancreas. These lesions, called "duct lesions," have even been identified in pancreata years before patients develop infiltrating carcinoma. Molecular genetic analysis of these lesions has revealed that they frequently harbor many of the same alterations present in infiltrating carcinoma of the pancreas. These alterations include activation of K-ras and inactivation of p16, p53 and, rarely BRCA2. CONCLUSIONS From these morphologic and molecular observations, we can now develop a progression model for the development of infiltrating carcinoma of the pancreas. Infiltrating carcinomas of the pancreas may arise from pancreatic duct lesions, and the progression of duct lesions to infiltrating cancer is associated with the accumulation of generalized and specific genetic alterations.

[1]  A. Abioye,et al.  Pancreatic carcinoma. , 2020, Journal of the National Medical Association.

[2]  R. Hruban,et al.  Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. , 1998, Cancer research.

[3]  R H Hruban,et al.  Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. , 1998, The American journal of surgical pathology.

[4]  K. Ohtsubo,et al.  Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  C. Moskaluk,et al.  p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. , 1997, Cancer research.

[6]  A. Gazdar,et al.  K-ras mutations and allelic loss at 5q and 18q in the development of human pancreatic cancers , 1997, International journal of pancreatology : official journal of the International Association of Pancreatology.

[7]  Steven Gallinger,et al.  Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients , 1997, Nature Genetics.

[8]  S. Goodman,et al.  Tumor-suppressive pathways in pancreatic carcinoma. , 1997, Cancer research.

[9]  C. Moskaluk,et al.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. , 1996, Cancer research.

[10]  P. Goodfellow,et al.  Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. , 1996, Journal of the National Cancer Institute.

[11]  W. Schmiegel,et al.  Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. , 1996, Gastroenterology.

[12]  T. Goodrow,et al.  Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. , 1996, Cancer research.

[13]  S. Nordling,et al.  Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. , 1996, Oncology.

[14]  T. Sekiya,et al.  Sensitive detection of loss of heterozygosity in the TP53 gene in pancreatic adenocarcinoma by fluorescence‐based single‐strand conformation polymorphism analysis using blunt‐end DNA fragments , 1996, Genes, chromosomes & cancer.

[15]  J. Niederhuber,et al.  The national cancer data base report on pancreatic cancer , 1995, Cancer.

[16]  P. Goodfellow,et al.  Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas , 1995, Genes, chromosomes & cancer.

[17]  R. Hruban,et al.  Allelotype of pancreatic adenocarcinoma using xenograft enrichment. , 1995, Cancer research.

[18]  L. Pradayrol,et al.  Identification of K-ras Mutations in Pancreatic Juice in the Early Diagnosis of Pancreatic Cancer , 1995, Annals of Internal Medicine.

[19]  S. Goodman,et al.  Pancreaticoduodenectomy for Cancer of the Head of the Pancreas 201 Patients , 1995, Annals of surgery.

[20]  R. Hruban,et al.  Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma , 1994, Nature Genetics.

[21]  R. Hruban,et al.  Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. , 1994, Cancer research.

[22]  S. Goodman,et al.  Overexpression of p53 protein in adenocarcinoma of the pancreas. , 1994, American journal of clinical pathology.

[23]  R. Hruban,et al.  p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. , 1994, Cancer research.

[24]  C Caldas,et al.  Allelotype of pancreatic adenocarcinoma. , 1994, Cancer research.

[25]  J. Cameron,et al.  Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. , 1994, The American journal of pathology.

[26]  N. Pellegata,et al.  K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. , 1994, Cancer research.

[27]  H. Nagura,et al.  Varying grades of epithelial atypia in the pancreatic ducts of humans. Classification based on morphometry and multivariate analysis and correlated with positive reactions of carcinoembryonic antigen. , 1994, Archives of pathology & laboratory medicine.

[28]  S. Goodman,et al.  K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. , 1993, The American journal of pathology.

[29]  H. Saisho,et al.  Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. , 1993, Cancer research.

[30]  H. Friess,et al.  p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. , 1993, Cancer letters.

[31]  S. Hirohashi,et al.  Pancreatic adenocarcinomas frequently show p53 gene mutations. , 1993, The American journal of pathology.

[32]  A. Yanagisawa,et al.  Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. , 1993, Cancer research.

[33]  T. Urano,et al.  Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. , 1993, Annals of surgery.

[34]  K. Mangold,et al.  K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. , 1992, Cancer research.

[35]  O. Yokosuka,et al.  Analysis of ras gene mutations in biliary and pancreatic tumors by polymerase chain reaction and direct sequencing , 1990, Cancer.

[36]  H. Shiku,et al.  Frequent Glycine‐to‐Aspartic Acid Mutations at Codon 12 of c‐Ki‐ras Gene in Human Pancreatic Cancer in Japanese , 1990, Japanese journal of cancer research : Gann.

[37]  H. Obata,et al.  Frequency and Types of Point Mutation at the 12th Codon of the c‐Ki‐ras Gene Found in Pancreatic Cancers from Japanese Patients , 1989, Japanese journal of cancer research : Gann.

[38]  G. Fleuren,et al.  KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. , 1988, Nucleic acids research.

[39]  S. Saga,et al.  Relation of pancreatic duct hyperplasia to carcinoma , 1979, Cancer.

[40]  A. Cubilla,et al.  Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. , 1976, Cancer research.

[41]  Daan Brandenbarg.  The National. , 1892 .

[42]  D. Ofner,et al.  p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[43]  Y. Shiratori,et al.  Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. , 1996, Gastroenterology.